Treatment-resistant schizophrenia (TRS) often results in severe disability and functional
impairment. Currently, the diagnosis of TRS is largely exclusionary and emphasizes the …

Second-generation antipsychotics are widely used for the treatment of schizophrenia.
Aripiprazole (ARI) is classified as a third-generation antipsychotic drug with a high affinity for …

The wider use of clozapine is limited by the risk of agranulocytosis and the associated
requirement for monitoring of neutrophil counts. We searched local electronic patient …

Although clozapine is a highly efficacious schizophrenia treatment, it is under-prescribed
due to the risk of idiosyncratic drug-induced agranulocytosis (IDIAG). Clinical data indicate …

Background: Treatment-resistant schizophrenia is prevalent and difficult to manage, as
patients fail multiple antipsychotic trials before being considered as treatment-resistant …

The risk of idiosyncratic drug-induced agranulocytosis (IDIAG) markedly constrains the use
of clozapine, a neuroleptic with unparalleled efficacy. Most clozapine patients experience an …

This article reports on an American Society of Pharmacology and Therapeutics, Division of
Drug Metabolism and Disposition symposium held at Experimental Biology on April 2, 2022 …

Globally, schizophrenia is one of the main causes of disability. Approximately 1% of the
general population suffers from schizophrenia, and 30% of cases are unresponsive to …

Background Clozapine has unique effectiveness in treatment-resistant schizophrenia and is
known to cause immunological side-effects. A transient spike in neutrophils commonly …

Current antipsychotics used to treat schizophrenia have associated problems, including
serious side effects and treatment resistance. We recently identified a significant association …